Fruquintinib
Fruquintinib is a targeted oral medication classified as a small molecule kinase inhibitor that works by blocking vascular endothelial growth factor receptors (VEGFR-1, -2, and -3). By inhibiting these receptors, it prevents VEGF-mediated signaling that tumors use to develop new blood vessels (angiogenesis), thereby slowing tumor growth and spread. This medication is primarily used to treat adults with metastatic colorectal cancer who have previously received standard chemotherapy.
Fruquintinib is an oral targeted therapy that inhibits blood vessel growth to tumors by blocking VEGFR receptors, used in metastatic colorectal cancer.
Key facts at a glance
- ATC
- L01EK04
- RxNorm
- 2670179
- Generic
- Fruquintinib
- Class
- atc-l01
- Brands
- Fruzaqla
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- capsule
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Fruquintinib is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have progressed following standard chemotherapy and who have adequate organ function.
Fruquintinib is a selective small molecule kinase inhibitor that targets VEGFR-1, -2, and -3 receptors. By blocking these receptors, it inhibits VEGF-mediated endothelial cell proliferation and new blood vessel formation (angiogenesis) that tumors need to grow and metastasize.
Common side effects may include hypertension, fatigue, and proteinuria. Patients should be monitored for signs of bleeding, gastrointestinal perforation, and wound healing complications. Regular blood pressure monitoring is required during treatment. Fruquintinib should be discontinued if severe hypertension cannot be controlled or if serious adverse events occur.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy